


# PRODUCT INFORMATION



## Halicin

Item No. 30436

**CAS Registry No.:** 40045-50-9  
**Formal Name:** 5-[(5-nitro-2-thiazolyl)thio]-1,3,4-thiadiazol-2-amine  
**Synonym:** SU 3327  
**MF:** C<sub>5</sub>H<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S<sub>3</sub>  
**FW:** 261.3  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 293, 339 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Halicin is supplied as a crystalline solid. A stock solution may be made by dissolving the halicin in the solvent of choice, which should be purged with an inert gas. Halicin is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of halicin in these solvents is approximately 20 and 30 mg/ml, respectively.

### Description

Halicin is a JNK1 inhibitor (IC<sub>50</sub> = 0.7 μM).<sup>1,2</sup> It is selective for JNK1 over p38α, Furin, and lethal factor (IC<sub>50</sub>s = >100, >100, and >50 μM, respectively), as well as Akt at 100 μM.<sup>1</sup> Halicin inhibits TNF-α-induced phosphorylation of c-Jun in a cell-based assay (EC<sub>50</sub> = 6.23 μM). *In vivo*, halicin (25 mg/kg) reduces blood glucose levels and restores insulin sensitivity in insulin-insensitive mice. Halicin is active against carbapenem-resistant Enterobacteriaceae (MICs = 1-10 μg/ml), as well as multidrug-resistant *A. baumannii* and *P. aeruginosa* (MICs = 1-10 and 1-100 μg/ml, respectively).<sup>2</sup> It reduces the number of wound tissue colony forming units (CFUs) in a mouse model of *A. baumannii* wound infection. Halicin (15 mg/kg) also reduces fecal bacterial load in a mouse model of *C. difficile* infection.

### References

1. De, S.K., Stebbins, J.L., Chen, L.-H., *et al.* Design, synthesis, and structure-activity relationship of substrate competitive, selective, and *in vivo* active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. *J. Med. Chem.* **52**(7), 1943-1952 (2009).
2. Stokes, J.M., Yang, K., Swanson, K., *et al.* A deep learning approach to antibiotic discovery. *Cell* **180**(4), 688-702 (2020).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/20/2021

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)